The estimated Net Worth of Margaret A Hamburg is at least $3.84 Million dollars as of 23 February 2023. Margaret Hamburg owns over 136 units of Alnylam Pharmaceuticals Inc stock worth over $35,620 and over the last 21 years he sold ALNY stock worth over $2,300,100. In addition, he makes $1,499,340 as Independent Director at Alnylam Pharmaceuticals Inc.
Margaret has made over 3 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 136 units of ALNY stock worth $35,620 on 23 February 2023.
The largest trade he's ever made was selling 51,000 units of Alnylam Pharmaceuticals Inc stock on 19 May 2009 worth over $2,300,100. On average, Margaret trades about 3,037 units every 406 days since 2004. As of 23 February 2023 he still owns at least 136 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Margaret Hamburg stock trades at the bottom of the page.
Dr. Margaret A. Hamburg is an Independent Director of the Company. Dr. Hamburg currently serves as Foreign Secretary of the National Academy of Medicine and as Chair of the Board of the American Association for the Advancement of Science (AAAS). From May 2009 to April 2015, Dr. Hamburg served as the Commissioner of the U.S. Food and Drug Administration (FDA). From January 2001 to May 2009, Dr. Hamburg worked for the Nuclear Threat Initiative, first as Vice President for biological programs, then as Senior Scientist. From November 1997 to January 2001, Dr. Hamburg served as the Assistant Secretary for Planning and Evaluation in the Department of Health and Human Services. Prior to that, she was New York City’s health commissioner. Dr. Hamburg currently serves on a number of non-profit boards. She is also a fellow of the American College of Physicians and the AAAS, and member of Harvard University Global Advisory Council, the Harvard Medical School Board of Fellows, the World Dementia Council, the Global Health Scientific Advisory Committee for the Bill and Melinda Gates Foundation, the Dean’s Advisory Council for the George Washington School of Public Health and the Saw See Hock School of Public Health International Advisory Panel, and chairs the Joint Coordinating Group for the Coalition for Epidemic Preparedness Initiative (CEPI).
As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of Margaret Hamburg at Alnylam Pharmaceuticals Inc is $1,499,340. There are 6 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
Margaret Hamburg is 64, he's been the Independent Director of Alnylam Pharmaceuticals Inc since 2019. There are 6 older and 13 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
Margaret's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: